Literature DB >> 26374510

Overview of magnetic resonance imaging for management of relapsing-remitting multiple sclerosis in everyday practice.

C Oreja-Guevara1.   

Abstract

Although the value of magnetic resonance imaging (MRI) for diagnosis/differential diagnosis of patients with clinically isolated syndromes suggestive of multiple sclerosis (MS) is widely accepted, adoption of MRI into clinical practice to monitor disease evolution remains a work in progress. However, an accumulating body of evidence points to a central role for MRI in managing patients with relapsing-remitting MS along the disease continuum. Routine MRI surveillance provides insight into disease activity that is not evident clinically and this information, in turn, can be used to inform prognosis and guide treatment decisions. In Europe, practical guidelines have been developed to reduce the heterogeneity of imaging (both intracentre and intercentre) and improve the quality of MRI assessment and interpretation. Aimed at the general neurologist, this review explores some of the issues associated with MRI and examines evidence supporting its use for routine monitoring of MS patients in everyday practice.
© 2015 The Author(s) European Journal of Neurology © 2015 EAN.

Entities:  

Keywords:  diagnosis; disease-modifying therapy; magnetic resonance imaging; multiple sclerosis; neuroimaging; prognosis

Mesh:

Year:  2015        PMID: 26374510     DOI: 10.1111/ene.12800

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  6 in total

1.  Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes.

Authors:  Maria Di Gregorio; Lorenzo Gaetani; Paolo Eusebi; Piero Floridi; Antonella Picchioni; Giovanni Rosi; Andrea Mancini; Chiara Floridi; Francesca Baschieri; Lucia Gentili; Paola Sarchielli; Paolo Calabresi; Massimiliano Di Filippo
Journal:  J Neurol       Date:  2018-01-11       Impact factor: 4.849

2.  Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS.

Authors:  Nicola de Stefano; Frederik Barkhof; Xavier Montalban; Anat Achiron; Tobias Derfuss; Andrew Chan; Suzanne Hodgkinson; Alexandre Prat; Letizia Leocani; Klaus Schmierer; Finn Sellebjerg; Patrick Vermersch; Heinz Wiendl; Birgit Keller; Sanjeev Roy
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2022-06-14

Review 3.  Temperature sensitivity in multiple sclerosis: An overview of its impact on sensory and cognitive symptoms.

Authors:  Aikaterini Christogianni; Richard Bibb; Scott L Davis; Ollie Jay; Michael Barnett; Nikos Evangelou; Davide Filingeri
Journal:  Temperature (Austin)       Date:  2018-09-05

Review 4.  The cerebrospinal fluid in multiple sclerosis: far beyond the bands.

Authors:  Renan Barros Domingues; Gustavo Bruniera Peres Fernandes; Fernando Brunale Vilela de Moura Leite; Charles Peter Tilbery; Rodrigo Barbosa Thomaz; Gisele Sampaio Silva; Cristóvão Luis Pitangueira Mangueira; Carlos Augusto Senne Soares
Journal:  Einstein (Sao Paulo)       Date:  2017 Jan-Mar

5.  Standardized quality metric system for structural brain magnetic resonance images in multi-center neuroimaging study.

Authors:  Michael E Osadebey; Marius Pedersen; Douglas L Arnold; Katrina E Wendel-Mitoraj; For The Alzheimer's Disease Neuroimaging Initiative
Journal:  BMC Med Imaging       Date:  2018-09-17       Impact factor: 1.930

6.  Impact of disease-modifying therapies on MRI and neurocognitive outcomes in relapsing-remitting multiple sclerosis: a protocol for a systematic review and network meta-analysis.

Authors:  Samuel Lees; Mathew Dicker; Jie En Ku; Varun Chaganti; Matthew Mew-Sum; Nick Wang; Angela Smith; Christopher Oldmeadow; Wooi Lynn Goon; Marc Bevan; Danielle Lang; Madeleine Hinwood
Journal:  BMJ Open       Date:  2021-11-02       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.